MedTrace Logo

Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes

NCT05573477 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 248

Last updated 2023-02-01

No results posted yet for this study

Summary

The purpose of this study is to evaluate safety and efficacy of ATB-1011 and ATB-1012 co-administration in patients with essential hypertension and type II diabetes mellitus

Conditions

  • Essential Hypertension
  • Diabetes Mellitus, Type 2

Interventions

DRUG

ATB-1011

Oral tablet

DRUG

ATB-1012

Oral tablet

DRUG

ATB-1013

Oral tablet

DRUG

ATB-1011 placebo

Placebo matched to ATB-1011

DRUG

ATB-1012 placebo

Placebo matched to ATB-1012

DRUG

ATB-1013 placebo

Placebo matched to ATB-1013

Sponsors & Collaborators

  • Autotelicbio

    lead INDUSTRY

Principal Investigators

  • James Jun, MD · Autotelicbio

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-16
Primary Completion
2024-01-31
Completion
2024-06-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05573477 on ClinicalTrials.gov